{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+placebo", "query": { "intervention": "Rivaroxaban placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rivaroxaban+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T13:00:58.457Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00439725", "title": "Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1197, "start_date": "2007-02", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 25, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Melbourne", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00439725" }, { "nct_id": "NCT00362232", "title": "Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Placebo: tablet of Rivaroxaban", "type": "DRUG" }, { "name": "Placebo: syringes of Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3148, "start_date": "2006-06", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 36 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00362232" }, { "nct_id": "NCT04593784", "title": "Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ciraparantag", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Point-of-Care Coagulometer (investigational device)", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 41, "start_date": "2021-10-13", "completion_date": "2023-08-26", "has_results": true, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 3, "location_summary": "South Miami, Florida • Secaucus, New Jersey • San Antonio, Texas", "locations": [ { "city": "South Miami", "state": "Florida" }, { "city": "Secaucus", "state": "New Jersey" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04593784" }, { "nct_id": "NCT02111564", "title": "A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure", "Respiratory Insufficiency", "Stroke Acute", "Infectious Diseases", "Rheumatic Diseases" ], "interventions": [ { "name": "Rivaroxaban, 10 mg", "type": "DRUG" }, { "name": "Rivaroxaban, 7.5 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 12024, "start_date": "2014-01-07", "completion_date": "2018-05-03", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 135, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 132 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02111564" }, { "nct_id": "NCT00571649", "title": "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" }, { "name": "Rivaroxaban placebo", "type": "DRUG" }, { "name": "Enoxaparin placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 8101, "start_date": "2007-12", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2016-09-15", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 121, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 107 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571649" }, { "nct_id": "NCT00403767", "title": "An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Stroke", "Embolism" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Matching placebo for Rivaroxaban arm (Warfarin placebo)", "type": "DRUG" }, { "name": "Matching placebo for Warfarin arm (Rivaroxaban placebo)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14269, "start_date": "2006-12", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-04-29", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 295, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Pell City", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00403767" }, { "nct_id": "NCT01776424", "title": "Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prevention & Control" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Aspirin placebo", "type": "DRUG" }, { "name": "Rivaroxaban placebo", "type": "DRUG" }, { "name": "Pantoprazole", "type": "DRUG" }, { "name": "Pantoprazole placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27395, "start_date": "2013-02-28", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2022-11-28", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01776424" }, { "nct_id": "NCT04508023", "title": "A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19)" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard of Care (SOC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1284, "start_date": "2020-08-13", "completion_date": "2022-06-01", "has_results": true, "last_update_posted_date": "2023-07-18", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Oakland, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508023" }, { "nct_id": "NCT04504032", "title": "A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gates Medical Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2020-09-02", "completion_date": "2021-03-29", "has_results": true, "last_update_posted_date": "2021-10-22", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 17, "location_summary": "Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504032" }, { "nct_id": "NCT01877915", "title": "A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure", "Coronary Artery Disease" ], "interventions": [ { "name": "Rivaroxaban", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of care for heart failure and coronary artery disease", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 5081, "start_date": "2013-09-10", "completion_date": "2018-04-19", "has_results": true, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-09-27T13:00:58.457Z", "location_count": 115, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 112 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01877915" } ] }